Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
Last trade$16.77
Day change+$0.07 (+0.42%)
Day range$16.40 – $16.91
Volume1,103,455
Market cap$3.05B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$3.05B
Price / earnings
—
Price / book
62.54×
Price / sales
8.29×
EV / sales
8.44×
EV / EBITDA
52.76×
Profitability
Earnings per share
-$0.04
Return on assets
-1.53%
Return on equity
-13.32%
Dividend yield
0%
Liquidity and leverage
Debt / equity
3.89×
Current ratio
2.15×
Quick ratio
1.58×
Cash ratio
0.97×
Cash flow
Price / cash flow
41.43×
Price / free cash flow
42.01×
Free cash flow
$72.62M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for XERS, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$107.23M
$92.1M
$83.13M
$85.81M
$74.38M
$71.54M
$60.12M
$60.1M
Cost of revenue
$12.43M
$12.51M
$10.57M
$10.95M
$11M
$11.9M
$8.73M
$9.48M
Gross profit
$94.8M
$79.59M
$72.55M
$74.86M
$63.38M
$59.64M
$51.39M
$50.62M
Selling, general and administrative
$64.11M
$61.04M
$53.14M
$47.5M
$46.46M
$44.39M
$44.02M
$40.14M
Research and development
$11.06M
$10.67M
$8.78M
$7.87M
$7.48M
$8.06M
$7.75M
$6.09M
Total operating expenses
$77.88M
$74.42M
$64.64M
$58.09M
$56.65M
$55.16M
$54.48M
$48.94M
Operating income
$16.92M
$5.17M
$7.92M
$16.77M
$6.73M
$4.48M
-$3.09M
$1.68M
Interest expense
-$6.46M
-$6.95M
-$6.88M
-$7.15M
-$7.27M
-$7.36M
-$7.31M
-$5.01M
Income before taxes
$11.29M
-$31.1M
$2.23M
$11.08M
$621K
-$1.93M
-$9.22M
-$5.11M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
$11.29M
-$31.1M
$2.23M
$11.08M
$621K
-$1.93M
-$9.22M
-$5.11M
Net income attributable to common shareholders
$11.29M
-$31.1M
$2.23M
$11.08M
$621K
-$1.93M
-$9.22M
-$5.11M
EBITDA
$19.95M
$8.21M
$10.96M
$19.82M
$9.78M
$7.52M
-$65K
$4.7M
Basic earnings per share
$0.06
-$0.18
$0.01
$0.07
$0.00
-$0.01
-$0.06
-$0.03
Diluted earnings per share
$0.06
-$0.18
$0.01
$0.06
$0.00
-$0.01
-$0.06
-$0.03
Recent news
Company coverage with links to the original publishers.
Xeris Biopharma reported strong Q2 2025 financial results, with revenue jumping 48.8% year-over-year to $71.5 million, driven by significant growth in Recorlev sales. The company raised its full-year revenue guidance and showed a positive turn in adjusted EBITDA.
Xeris Biopharma (XERS) delivered earnings and revenue surprises of -16.67% and 2.21%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
MediWound (MDWD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Xeris Biopharma's financial success in compounding healthcare investing may be uncertain due to competition and FDA approval risks. Read more on XERS stock here.